Oppenheimer Starts Xeris Pharmaceuticals (XERS) at Outperform, 'successful commercial execution will continue to drive top-line growth'
Tweet Send to a Friend
(Updated - March 27, 2024 4:04 PM EDT)
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Pharmaceuticals (NASDAQ: XERS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Pharmaceuticals (NASDAQ: XERS) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
